Results 91 to 100 of about 2,875 (114)

A Severe Symptomatic Case of Amyloid-Related Imaging Abnormalities After Donanemab Infusion. [PDF]

Cureus
Harikumar N, Gupta M, Al Janabi T, Mand KK.   +3 more
europepmc   +1 more source

Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations. [PDF]

Clin Interv Aging
Zrineh A, Akwan R, Darawsheh R, Nasser A, Elsharkawy MM.   +4 more
europepmc   +1 more source

Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia. [PDF]

Med J Aust
Gao L, Watson R, Yassi N.
europepmc   +1 more source

Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers. [PDF]

Clin Interv Aging
Bailey-Taylor MJ, Morrow P, Hendrix J, Galluzzi KE, Sharafsaleh G.   +4 more
europepmc   +1 more source

Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer's Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. [PDF]

Dement Neurocogn Disord
Shim Y.
europepmc   +1 more source

What should convince a clinician of disease modification in Alzheimer's disease clinical trials? [PDF]

Alzheimers Dement
Hazan J, Liu KY, Howard R.
europepmc   +1 more source

Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions. [PDF]

Front Neurol
Zupan M, Prelog PR, Kramberger MG, Frol S.   +3 more
europepmc   +1 more source

Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease. [PDF]

J Prev Alzheimers Dis
Benussi A, Agosta F, Agnello L, Alfano AR, Altini M, Antico A, Basilico S, Bellelli G, Bonanni L, Bottini G, Bozzali M, Brignoli O, Bruno G, Cagnin A, Calloni SF, Cappa SF, Caraci F, Cecchin D, Ciaccio M, Cocozza S, Cosottini M, De Leo D, Falini A, Gaetani L, Gandolfo N, Gotta F, Lodi R, Logroscino G, Marcello E, Marra C, Marrocco W, Morbelli S, Mecocci P, Mossello E, Palleschi L, Palumbo P, Pantoni L, Parnetti L, Roccatagliata L, Sorbi S, Spadin P, Splendiani A, Tessitore A, Ungar A, Zappalà G, Padovani A.   +45 more
europepmc   +1 more source

The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Dinnerstein E.
europepmc   +1 more source

Letter to the Editor "Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J-ADNI Study". [PDF]

Geriatr Gerontol Int
Pradhan S.
europepmc   +1 more source